As of 1 November 2023, the new National Immunisation Program (NIP) Shingrix program has commenced.  

Shingrix is an inactivated vaccine used for the prevention of zoster (shingles). It has been registered for use in Australia since 2018 but until now it has only been available to purchase privately. 

Shingrix has replaces Zostavax on the NIP. Zostavax is a live zoster vaccine, which could not be administered to immunocompromised people. 

Shingrix is funded for: 

  • all people aged 65 years and over 
  • First Nations people aged 50 years and over 
  • people aged 18 years and over with certain immunocompromising conditions (history of haematopoietic stem cell transplant, solid organ transplant, blood cancer, and advanced or untreated HIV). 

MVEC: Zoster (shingles)